Overview

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

Status:
Terminated
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.
Phase:
Phase 2
Details
Lead Sponsor:
Ronald Weigel
University of Iowa
Collaborator:
AstraZeneca